The U.S. FDA released briefing documents ahead of the Dermatologic and Ophthalmic Drugs Advisory Committee meeting scheduled ...

Wall Street reacted with satisfaction to Genmab A/S phase III data proving that doctors can gain oomph against cancer by ...

Boston Scientific Corp. revised its guidance downwards for 2026, again, as it continues to have a challenging year. In ...

A perhaps unexpected theme of the first day of the European Society for Cell and Gene Therapy’s 2026 annual congress is how ...

The endocannabinoid system is a neuromodulatory network that plays a crucial role in brain development and neuronal signaling ...

Mycobacterium tuberculosis remains a leading cause of infectious disease-mediated death, with 10.8 million reported cases of ...

Already tagged with a potential “best-in-class” description by industry analysts on the back of positive phase III data unveiled earlier this year, Eli Lilly and Co.’s retatrutide turned up another ...

Idorsia Ltd. is branching into a new indication for its dual orexin 1 and 2 antagonist drug Quviviq (daridorexant), after a phase II pediatric insomnia trial showed unexpected improvements in the ...

Astellas Pharma Inc. has taken an exclusive option to license DAX-044 from Melbourne, Australia-based Audax Biosciences, ...

AC Immune SA has reported new microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors potentially useful for the treatment of Alzheimer’s disease.

Respiratory syncytial virus (RSV) causes approximately 3.6 million hospitalizations and 100,000 deaths annually among ...

Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor ...